Forge Therapeutics Scientific Co-Founder Bestowed Prestigious National Chemistry Award

SAN DIEGO, Aug. 19, 2015 /PRNewswire/ -- Forge Therapeutics, Inc., a biotechnology start-up developing novel small molecule inhibitors that target metalloproteins announced today Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in the Department of Chemistry and Biochemistry at the University of California, San Diego is the recipient of the Arthur C. Cope Scholar Award administered by the American Chemical Society. 

The Arthur C. Cope Scholar Award is a prize awarded for excellence and achievement in the field of organic chemistry.  Dr. Cohen was named one of the ten Arthur C. Cope Scholars at the American Chemical Society national meeting being held in Boston from August 16-20, 2015 for his pioneering work on metalloprotein chemistry. 

"It is with great pride at Forge Therapeutics that we congratulate Dr. Cohen on being named an Arthur C. Cope Scholar," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  "This award is a high honor in the field of chemistry and further validates the Forge Therapeutics drug discovery platform."

To learn more about the Arthur C. Cope Scholar Award please visit: http://www.acs.org/content/acs/en/funding-and-awards/awards/national/recipients/2016-national-award-recipients.html

About Forge Therapeutics, Inc.

Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  Forge is uniquely positioned to discover compounds that inhibit metalloproteins through an innovative process developed at the University of California at San Diego.  Forge possesses rights to key intellectual property for metalloprotein inhibitors. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com

Contact:
[email protected]

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO

SOURCE Forge Therapeutics, Inc.

Related Links

http://www.ForgeTherapeutics.com